Eupraxia Pharmaceuticals - EPRX Company profit before taxes, interest and amortization
Geopolitical tensions and logistical barriers are limiting the expansion of new drugs, narrowing target markets. The operating profit of Eupraxia Pharmaceuticals (EPRX) on this chart allows for an assessment of financial stability against this backdrop, where the value of 0.00 shows the current figure. Growth potential is driven by a flexible R&D staff of biochemists and the innovative DiffuSphere system for combating chronic pain.
Eupraxia Pharmaceuticals Inc. (EPRX) - metric breakdowns and financial figures
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Eupraxia Pharmaceuticals|EPRX - Long-Term Debt to Capital|Current Liabilities to Capital eupraxiapharma.com|EPRX - Company Total Debt|Debts to Book Capitalization Eupraxia Pharmaceuticals, Inc.|EPRX - Company Long-Term Debt|Current Liabilities Eupraxia Pharmaceuticals|Intermediate Coverage Ratio eupraxiapharma.com
- earnings and market ratios statistics:
EPRX - Net Profit|Projected Future Earnings Eupraxia Pharmaceuticals|EPRX - Price to Earnings Ratio|Price to Future Earnings Ratio Eupraxia Pharma|EPRX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Eupraxia Pharmaceuticals Inc.|EPRX - Operating profit EBITDA|Net earnings per share (EPS TTM) Eupraxia Pharmaceuticals|EPRX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months eupraxiapharma.com|EPRX - Earnings per share growth in current year|Net earnings per share change forecast for next year Eupraxia Pharmaceuticals
- sales revenue and business income indicators:
Fundamental company valuation:EPRX (Eupraxia Pharmaceuticals Inc.)
The patent protection of Eupraxia Pharmaceuticals (EPRX) and the complexity of establishing sterile laboratories create a sustainable market moat that directly impacts cash flow. The EBITDA_Co metric reflects the daily liquidity inflow from core operations, aggregating institutional expectations regarding business efficiency, where any movement in the curve signals the balance between current yield and long-term market risks.
Competitors of Eupraxia Pharmaceuticals (EPRX)
Company profit before taxes, interest and amortization HLN (Haleon plc)|KVUE: Operating profit before deduction of amortization|Verona Pharma - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharma - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization perrigo.com PRGO|Profit before payment of interest, taxes and amortization Alvotech SA (ALVO)|LQDA (Liquidia Corp) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA GLPG (Galapagos N.V.)|Operating profit EBITDA ANI Pharmaceuticals Corp ANIP|Afrezza - Operating profit EBITDA|amphastar.com (AMPH) - Operating profit before deduction of amortization|PCRX: Operating profit EBITDA|SPRY - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Theravance|Profit before interest, taxes and amortization Aquestive Corp AQST|Operating profit EBITDA SCPH|TECX - Profit before interest, taxes and amortization|Tonix Pharmaceuticals Holding Corp. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization SXTC|BHST: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Invizyne|Oramed Pharmaceuticals Inc. (ORMP) - Profit before payment of interest, taxes and amortization|ENTX (Entera Bio Ltd) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization HYFT|ABVC BioPharma, Inc. - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA CPIX|Operating income before deduction of amortization Quantum BioPharma Corp|Profit before payment of interest, taxes and amortization FibroGen FGEN|Operating profit EBITDA telomirpharma.com TELO|Rani Therapeutics Inc - Operating profit EBITDA|Income before deduction of interest, taxes and amortization SNYR (synergychc.com)|Rallybio (RLYB) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Lexaria Bioscience Corp|Operating profit before deduction of amortization PULM|PTHL - Operating profit before depreciation charges|Operating profit EBITDA APM|Operating income before deduction of amortization Lyra Therapeutics|Profit before payment of interest, taxes and amortization Impact BioMedical Inc IBO|TNFA - Operating profit before deduction of amortization|cbdMD, Inc. - Operating profit EBITDA|Income before deduction of interest, taxes and amortization PRFX (PainReform Ltd.)|CYTO (altamiratherapeutics.com) - Operating profit before deduction of amortization|LIPO: Company profit before taxes, interest and amortization|OPTN (Optinose) - Operating profit EBITDA|Operating profit before deduction of amortization Pieris (PIRS)|Profit before payment of interest, taxes and amortization Procaps Group S.A. (PROC)|Operating profit EBITDA petrospharma.com (PTPI)|Profit before payment of interest, taxes and amortization Qilian International Holding QLI|Income before deduction of interest, taxes and amortization SLRN|TFF Pharmaceuticals, Inc. - Operating profit EBITDA
